In addition, when we simultaneously treated the BRCA1 knock-down ovarian cancer cells with dobutamine and the ADRB1-specific antagonist atenolol, the levels of cAMP decreased to the basal level, whereas the ADRB2-specific antagonist ICI-118551 had no inhibitory effect (Figure 4E). Here, ADRB1 is linked to ovarian cancer.